Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study (Q43269486)

17 November 2017

Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study (English)

1 reference

17 November 2017

1 reference

1 reference

1 reference

1 reference

4

Norah A Terrault

1 reference

17 November 2017

Donna M Evon

1

1 reference

17 November 2017

Darmendra Ramcharran

2

1 reference

17 November 2017

Steven H Belle

3

1 reference

17 November 2017

Robert J Fontana

5

1 reference

17 November 2017

Michael W Fried

6

1 reference

17 November 2017

Virahep-C Study Group

7

1 reference

17 November 2017

language of work or name

English

0 references

publication date

29 September 2009

1 reference

The American Journal of Gastroenterology

17 November 2017

1 reference

17 November 2017

104

1 reference

17 November 2017

12

1 reference

17 November 2017

2949-2958

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

17 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Hepatitis C, interferon alfa, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Psychiatric management of the hepatitis C patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Screening for depression in primary care clinics: the CES-D and the BDI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

The utility of the CES-D as a depression screening measure among low-income women attending primary care clinics. The Center for Epidemiologic Studies-Depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Depression, disease severity, and sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Self-report measures among transplant candidates: the impact of evaluative situations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Social desirability, perceived stress, and PACT ratings in lung transplant candidates: A preliminary investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

The phenomenology and treatment of interferon-induced depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Social support and health: a review of physiological processes potentially underlying links to disease outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Social and emotional support and its implication for health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Reduction of Cancer-Specific Thought Intrusions and Anxiety Symptoms With a Stress Management Intervention Among Women Undergoing Treatment for Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.528

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.528

1 reference

17 November 2017

1 reference